PMO Interview with the Innovator Series: Volume 2

Peter Hirth, PhD

Video Categories: PMO Interview with the Innovator Series

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
July 17, 2018

Explaining Treatment Regimens to Patients with HR+/HER2–Metastatic Breast Cancer

Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2–metastatic breast cancer regarding how long their treatment will last and how it will impact them.

July 17, 2018

How to Foster Communication Among all Members of the Cancer Care Team with Pathologists to Deliver Individualized Treatment for Patients with Lung Cancer

Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.